Vivek Subbiah: Pralsetinib has received FULL FDA approval

Exciting News for RET+ patients!

Pralsetinib has received FULL FDA approval!

From treating the 1st patient in the universe to getting accelerated approval, & now full approval all based on a Phase 1/2 trial, it’s been an incredible journey.

Grateful to patients, caregivers, investigators, Blueprint Meds team, & FDA for making this now  available as another option for RET+ patients with NSCLC Precision medicine for the win.

Links to the paper:

1. Pre-clinical & Phase 1  https://tinyurl.com/2wxysehf
2. RET + NSCLC  https://tinyurl.com/y8ded4db
3. RET+ Thyroid  https://tinyurl.com/5eea36bh
4. RET+ Tissue agnostic  https://tinyurl.com/2h8rt8dy
5. Full approval  https://tinyurl.com/5t3hzbxp

Source: Vivek Subbiah / Twitter